Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Caforio takes CEO role as BMS faces tough year with promising new drugs

Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today at Bristol-Myers Squibb, the question will be how well he speaks dollars and cents.

Zoetis, under pressure from activist investor Ackman, will offload 10 plants to cut costs

Animal health leader Zoetis is using a move out of the Amgen playbook, whacking on manufacturing to cut costs and appease an aggressive activist investor.

Novo pumps up hemophilia drug production with $225M plant

Expecting demand for its hemophilia products to grow, diabetes drug specialist Novo Nordisk is kicking off construction of a $225 million plant at its extensive production site in Kalundborg.

GSK weighing scrapping investor payout to boost dividend instead

Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.

Gilead ready to take the cash from hep C superstars and buy something

Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.

FDA opens floodgates to generics of Bristol-Myers' Abilify

Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic Abilify, the FDA opened the floodgates to generics of the blockbuster.

Daiichi Sankyo gets EMA recommendation on clot buster

Japan's Daiichi Sankyo got some helpful news today as its works desperately to bring new revenue in the door ahead of next year's patent loss on its foundational product Benicar. The advisory group of the European Medicines Agency (EMA) recommended approval of Daiichi's new generation anticoagulant in Europe.

Reckitt Benckiser makes out big time on the misery of U.S. flu sufferers

The fact that this flu season's vaccines were not very effective was bad news for people hoping to avoid the condition but great news for the U.K.'s Reckitt Benckiser Group, which racked up an impressive first quarter on sales of over-the-counter flu meds like Mucinex.

AstraZeneca sales retreat in its effort to achieve huge growth by 2023

AstraZeneca CEO Pascal Soriot, while fighting off the takeover attempt by Pfizer, promised that the company would hit annual revenue of $45 billion by 2023. Now he will be measured by that promise quarter by quarter and today he fell a little short.